Analysts’ Viewpoint
Growth in clinical trials, technological advancement in image-based cytometry, and increase in partnerships & M&A activities are fueling global image-based cytometry in cell analysis market growth. Rise in adoption of image-based cytometry for drug discovery and development is also driving market expansion. Furthermore, rise in spending capacity of end-users, high prevalence of chronic diseases, and improved healthcare infrastructure in emerging economies are creating significant image-based cytometry in cell analysis market opportunities.
High cost of instruments and limited availability of skilled labors are expected to hamper market statistics during the forecast period. Manufacturers and service providers in the image-based cytometry in cell analysis market are focusing on developing products and services that are tailored to the needs and budget constraints of emerging markets.
Image-based cytometry in cell analysis is a cutting-edge technology used in biological research and clinical diagnostics to analyze cells and cellular processes. It combines the principles of flow cytometry and microscopy with advanced image analysis algorithms, enabling researchers to obtain detailed information about cell populations and their characteristics.
Traditionally, flow cytometry has been the gold standard for cell analysis, allowing the detection and quantification of multiple cellular parameters simultaneously. However, it has limitations when it comes to visualizing cellular morphology and spatial relationships. Imaging flow cytometry overcomes these limitations by capturing high-resolution images of cells and analyzing them using sophisticated image analysis software.
Companies are increasing their market share by implementing various strategies such as new product development, acquisitions, employing effective advertising, and pricing products and services efficiently. For instance, in February 2023, Cytek Biosciences, Inc. and DiaSorin announced that Cytek would acquire the Flow Cytometry & Imaging (FCI) business unit from Luminex Corporation, a DiaSorin subsidiary. This acquisition would broaden Cytek's global commercial footprint by incorporating an existing installed base of over 7000 instruments.
In January 2022, Becton, Dickinson and Company collaborated with the European Molecular Biology Laboratory (EMBL) to evaluate the potential of flow cytometry with imaging technology in transforming immunology, cell biology, and genomics research and enabling new cell-based therapeutic discovery.
In May 2023, Becton, Dickinson and Company launched a new cell sorting instrument, BD FACSDiscover S8 Cell Sorter, globally. This instrument is the first in the world to combine two breakthrough technologies, namely spectral flow cytometry and real-time imaging technology. This new instrument offers researchers an unprecedented level of insight into cell behavior and function, and has the potential to transform the field of cell research.
These strategies help companies attain a sustained competitive advantage over their competitors.
Improvement in end-users' purchasing power in emerging economies is a crucial opportunity for players operating in the image-based cytometry in cell analysis market. Rise in purchasing power increases the spending capacity of end-users and enables them to invest in high-cost instruments.
Emerging markets in Asia, Africa, and Latin America are experiencing rapid economic development owing to increase in investment in research & development, healthcare, and biotechnology.
In November 2022, Visiopharm and Standard BioTools announced a partnership to develop complete image analysis solutions that would be packaged with the Hyperion and Hyperion+ Imaging Systems. Hyperion and Hyperion+ Imaging Systems are advanced imaging platforms that enable high-resolution imaging of cells and tissues, providing researchers with a powerful tool for investigating complex biological systems.
In terms of end-user, the global market has been segmented into biotechnology & pharmaceutical companies, academia, cosmetic industry, contract research organizations, and contract development & manufacturing organizations. As per the image-based cytometry in cell analysis industry research report, the biotechnology & pharmaceutical companies segment is projected to lead the global market in the near future.
Technological advancement in image-based cytometry enables biotechnology & pharmaceutical companies to analyze large datasets and extract meaningful insights from complex cellular images and assist them in drug development. Image-based cytometry technology can be integrated with other advanced technologies, such as artificial intelligence and high-content imaging cytometry, to increase the scope of applications in several biotechnology & pharmaceutical companies.
Based on therapeutic area, the oncology & immune-oncology segment is estimated to dominate the global market during the forecast period.
The oncology & immune-oncology segment can be further classified into small molecules, protein-based therapeutics, cell therapy, and nucleic acid-based drugs. The nucleic acid-based drugs sub-segment is anticipated to expand at a high CAGR from 2023 to 2031.
Reliable and precise methods for detecting cancer and categorizing patients are fundamental in modern oncology. In clinical practice, various techniques are employed to obtain cancer specimens. Recent advancements in engineering and advanced AI have led to the development of a new generation of image cytometers that can operate effectively with minimal biological material.
Image cytometers offer quantitative and qualitative information about cancer cells and their characteristics. They aid in accurate diagnosis, prognostic assessment, treatment monitoring, and research, ultimately contributing to improved patient care and outcomes in the field of oncology. Hence, image-based cytometry in cell analysis market demand is expected to rise in the near future due to the increase in cases of cancers.
The U.S. accounted for major image-based cytometry in cell analysis market share in 2022. According to the latest image-based cytometry in cell analysis market forecast, the U.S. is projected to dominate the global industry during the forecast period.
Rise in number of genomic screening projects and increase in demand for cell-based diagnostics and characterization of cells in healthy and diseased states are the key factors contributing to the market progress in the U.S.
The market in China is anticipated to grow at a rapid pace during the forecast period. Increase in adoption of image-based cytometry technology among various players and researchers in China is fueling market development. Market players in China are also exploring opportunities in personalized therapies.
The global landscape is fragmented, with the presence of several manufacturers. Key players operating in the market are PerkinElmer, Inc., Merck KGaA, Sartorius AG, Thermo Fisher Scientific, Inc., Carl Zeiss Meditec AG, Charles River Laboratories, Yokogawa Electric Corporation, and Nanolive SA. These players are following the trends in image-based cytometry technologies to avail lucrative revenue opportunities.
Prominent players in the image-based cytometry in cell analysis market report have been profiled based on parameters such as product portfolio, latest developments, company overview, business strategies, business segments, and financial overview.
| Attribute | Detail |
|---|---|
| Size in 2022 | US$ 2.7 Bn |
| Forecast (Value) in 2031 | More than US$ 6.5 Bn |
| Growth Rate (CAGR) | 10.4% |
| Forecast Period | 2023-2031 |
| Historical Data Available for | 2017-2022 |
| Quantitative Units | US$ Bn for Value |
| Market Analysis | It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, and opportunities. |
| Competition Landscape |
|
| Format | Electronic (PDF) + Excel |
| Segmentation |
|
| Regions/Countries Covered |
|
| Companies Profiled |
|
| Customization Scope | Available upon request |
| Pricing | Available upon request |
It was valued at US$ 2.7 Bn in 2022
It is anticipated to reach more than US$ 6.5 Bn by 2031
The CAGR is projected to be 10.4% during the forecast period
Increase in number of clinical trials and technological advancements in image-based cytometry
The biotechnology & pharmaceutical companies end-user segment held major share of over 50.0% in 2022
Demand for image based cytometry in cell analysis is likely to rise in the country during the forecast period
PerkinElmer, Inc., Merck KGaA, Sartorius AG, Thermo Fisher Scientific, Inc., Carl Zeiss Meditec AG, Charles River Laboratories, Yokogawa Electric Corporation, and Nanolive SA
1. Preface
1.1. Market Definition and Scope
1.2. Key Research Objectives
2. Assumptions and Research Methodology
3. Market Overview
3.1. Overview
3.2. Market Dynamics
3.2.1. Drivers
3.2.2. Restraints
3.2.3. Opportunities
4. Global Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by End-user
4.1. Introduction & Definition
4.2. Key Findings/Developments
4.3. Market Value Forecast, by End-user, 2017-2031
4.3.1. Biotechnology & Pharmaceutical Companies
4.3.2. Academia
4.3.3. Cosmetic Industry
4.3.4. Contract Research Organizations
4.3.5. Contract Development & Manufacturing Organizations
5. Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by Therapeutic Area
5.1. Introduction & Definition
5.2. Key Findings/Developments
5.3. Market Value Forecast, by Therapeutic Area, 2015-2031
5.3.1. Oncology & Immune-oncology
5.3.1.1. Small Molecules
5.3.1.2. Protein-based Therapeutics
5.3.1.3. Cell Therapy
5.3.1.4. Nucleic Acid-based Drugs
5.3.2. Cardiovascular & Metabolic Diseases
5.3.2.1. Small Molecules
5.3.2.2. Protein-based Therapeutics
5.3.2.3. Cell Therapy
5.3.2.4. Nucleic Acid-based Drugs
5.3.3. Immunology
5.3.3.1. Small Molecules
5.3.3.2. Protein-based Therapeutics
5.3.3.3. Cell Therapy
5.3.3.4. Nucleic Acid-based Drugs
5.3.4. Rare Diseases
5.3.4.1. Small Molecules
5.3.4.2. Protein-based Therapeutics
5.3.4.3. Cell Therapy
5.3.4.4. Nucleic Acid-based Drugs
5.3.5. Neurological Diseases
5.3.5.1. Small Molecules
5.3.5.2. Protein-based Therapeutics
5.3.5.3. Cell Therapy
5.3.5.4. Nucleic Acid-based Drugs
5.3.6. Others
5.3.6.1. Small Molecules
5.3.6.2. Protein-based Therapeutics
5.3.6.3. Cell Therapy
5.3.6.4. Nucleic Acid-based Drugs
6. Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by Workplace
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Workplace, 2016-2031
6.3.1. Target Identification
6.3.2. Hit Generation & Lead Identification
6.3.3. Lead Optimization
6.3.4. In Vitro Preclinical Studies
6.3.5. In Vivo Preclinical Studies
6.3.6. Clinical Studies
7. Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by Country/Region
7.1. Key Findings
7.2. Market Value Forecast, by Country/Region, 2017-2031
7.2.1. U.S.
7.2.2. Europe
7.2.3. China
7.2.4. Rest of the World
8. U.S. Image-based Cytometry in Cell Analysis Market Analysis and Forecast
8.1. Introduction
8.1.1. Key Findings
8.2. Market Value Forecast, by End-user, 2017-2031
8.2.1. Biotechnology & Pharmaceutical Companies
8.2.2. Academia
8.2.3. Cosmetic Industry
8.2.4. Contract Research Organizations
8.2.5. Contract Development & Manufacturing Organizations
8.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
8.3.1. Oncology & Immune-oncology
8.3.1.1. Small Molecules
8.3.1.2. Protein-based Therapeutics
8.3.1.3. Cell Therapy
8.3.1.4. Nucleic Acid-based Drugs
8.3.2. Cardiovascular & Metabolic Diseases
8.3.2.1. Small Molecules
8.3.2.2. Protein-based Therapeutics
8.3.2.3. Cell Therapy
8.3.2.4. Nucleic Acid-based Drugs
8.3.3. Immunology
8.3.3.1. Small Molecules
8.3.3.2. Protein-based Therapeutics
8.3.3.3. Cell Therapy
8.3.3.4. Nucleic Acid-based Drugs
8.3.4. Rare Diseases
8.3.4.1. Small Molecules
8.3.4.2. Protein-based Therapeutics
8.3.4.3. Cell Therapy
8.3.4.4. Nucleic Acid-based Drugs
8.3.5. Neurological Diseases
8.3.5.1. Small Molecules
8.3.5.2. Protein-based Therapeutics
8.3.5.3. Cell Therapy
8.3.5.4. Nucleic Acid-based Drugs
8.3.6. Others
8.3.6.1. Small Molecules
8.3.6.2. Protein-based Therapeutics
8.3.6.3. Cell Therapy
8.3.6.4. Nucleic Acid-based Drugs
8.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
8.4.1. Target Identification
8.4.2. Hit Generation & Lead Identification
8.4.3. Lead Optimization
8.4.4. In Vitro Preclinical Studies
8.4.5. In Vivo Preclinical Studies
8.4.6. Clinical Studies
9. Europe Image-based Cytometry in Cell Analysis Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by End-user, 2017-2031
9.2.1. Biotechnology & Pharmaceutical Companies
9.2.2. Academia
9.2.3. Cosmetic Industry
9.2.4. Contract Research Organizations
9.2.5. Contract Development & Manufacturing Organizations
9.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
9.3.1. Oncology & Immune-oncology
9.3.1.1. Small Molecules
9.3.1.2. Protein-based Therapeutics
9.3.1.3. Cell Therapy
9.3.1.4. Nucleic Acid-based Drugs
9.3.2. Cardiovascular & Metabolic Diseases
9.3.2.1. Small Molecules
9.3.2.2. Protein-based Therapeutics
9.3.2.3. Cell Therapy
9.3.2.4. Nucleic Acid-based Drugs
9.3.3. Immunology
9.3.3.1. Small Molecules
9.3.3.2. Protein-based Therapeutics
9.3.3.3. Cell Therapy
9.3.3.4. Nucleic Acid-based Drugs
9.3.4. Rare Diseases
9.3.4.1. Small Molecules
9.3.4.2. Protein-based Therapeutics
9.3.4.3. Cell Therapy
9.3.4.4. Nucleic Acid-based Drugs
9.3.5. Neurological Diseases
9.3.5.1. Small Molecules
9.3.5.2. Protein-based Therapeutics
9.3.5.3. Cell Therapy
9.3.5.4. Nucleic Acid-based Drugs
9.3.6. Others
9.3.6.1. Small Molecules
9.3.6.2. Protein-based Therapeutics
9.3.6.3. Cell Therapy
9.3.6.4. Nucleic Acid-based Drugs
9.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
9.4.1. Target Identification
9.4.2. Hit Generation & Lead Identification
9.4.3. Lead Optimization
9.4.4. In Vitro Preclinical Studies
9.4.5. In Vivo Preclinical Studies
9.4.6. Clinical Studies
9.5. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Country/Sub-region, 2017-2031
9.5.1. EU5
9.5.2. U.K.
9.5.3. Switzerland
9.5.4. Rest of Europe
10. China Image-based Cytometry in Cell Analysis Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by End-user, 2017-2031
10.2.1. Biotechnology & Pharmaceutical Companies
10.2.2. Academia
10.2.3. Cosmetic Industry
10.2.4. Contract Research Organizations
10.2.5. Contract Development & Manufacturing Organizations
10.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
10.3.1. Oncology & Immune-oncology
10.3.1.1. Small Molecules
10.3.1.2. Protein-based Therapeutics
10.3.1.3. Cell Therapy
10.3.1.4. Nucleic Acid-based Drugs
10.3.2. Cardiovascular & Metabolic Diseases
10.3.2.1. Small Molecules
10.3.2.2. Protein-based Therapeutics
10.3.2.3. Cell Therapy
10.3.2.4. Nucleic Acid-based Drugs
10.3.3. Immunology
10.3.3.1. Small Molecules
10.3.3.2. Protein-based Therapeutics
10.3.3.3. Cell Therapy
10.3.3.4. Nucleic Acid-based Drugs
10.3.3.5. Nucleic Acid
10.3.4. Rare Diseases
10.3.4.1. Small Molecules
10.3.4.2. Protein-based Therapeutics
10.3.4.3. Cell Therapy
10.3.4.4. Nucleic Acid-based Drugs
10.3.5. Neurological Diseases
10.3.5.1. Small Molecules
10.3.5.2. Protein-based Therapeutics
10.3.5.3. Cell Therapy
10.3.5.4. Nucleic Acid-based Drugs
10.3.6. Others
10.3.6.1. Small Molecules
10.3.6.2. Protein-based Therapeutics
10.3.6.3. Cell Therapy
10.3.6.4. Nucleic Acid-based Drugs
10.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
10.4.1. Target Identification
10.4.2. Hit Generation & Lead Identification
10.4.3. Lead Optimization
10.4.4. In Vitro Preclinical Studies
10.4.5. In Vivo Preclinical Studies
10.4.6. Clinical Studies
11. Rest of the World Image-based Cytometry in Cell Analysis Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by End-user, 2017-2031
11.2.1. Biotechnology & Pharmaceutical Companies
11.2.2. Academia
11.2.3. Cosmetic Industry
11.2.4. Contract Research Organizations
11.2.5. Contract Development & Manufacturing Organizations
11.3. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Therapeutic Area, 2017-2031
11.3.1. Oncology & Immune-oncology
11.3.1.1. Small Molecules
11.3.1.2. Protein-based Therapeutics
11.3.1.3. Cell Therapy
11.3.1.4. Nucleic Acid-based Drugs
11.3.2. Cardiovascular & Metabolic Diseases
11.3.2.1. Small Molecules
11.3.2.2. Protein-based Therapeutics
11.3.2.3. Cell Therapy
11.3.2.4. Nucleic Acid-based Drugs
11.3.3. Immunology
11.3.3.1. Small Molecules
11.3.3.2. Protein-based Therapeutics
11.3.3.3. Cell Therapy
11.3.3.4. Nucleic Acid-based Drugs
11.3.4. Rare Diseases
11.3.4.1. Small Molecules
11.3.4.2. Protein-based Therapeutics
11.3.4.3. Cell Therapy
11.3.4.4. Nucleic Acid-based Drugs
11.3.5. Neurological Diseases
11.3.5.1. Small Molecules
11.3.5.2. Protein-based Therapeutics
11.3.5.3. Cell Therapy
11.3.5.4. Nucleic Acid-based Drugs
11.3.6. Others
11.3.6.1. Small Molecules
11.3.6.2. Protein-based Therapeutics
11.3.6.3. Cell Therapy
11.3.6.4. Nucleic Acid-based Drugs
11.4. Biotechnology & Pharmaceutical Companies Market Value Forecast, by Workplace, 2017-2031
11.4.1. Target Identification
11.4.2. Hit Generation & Lead Identification
11.4.3. Lead Optimization
11.4.4. In Vitro Preclinical Studies
11.4.5. In Vivo Preclinical Studies
11.4.6. Clinical Studies
12. Competition Landscape
12.1. Market Share Analysis, by Company (2022)
12.2. Company Profiles
12.2.1. Nanolive SA
12.2.1.1. Company Overview
12.2.1.2. Product Portfolio/Brands with its Description/Features
12.2.1.3. Strategic Overview/Recent Developments
12.2.1.4. SWOT Analysis
12.2.2. PerkinElmer, Inc.
12.2.2.1. Company Overview
12.2.2.2. Product Portfolio/Brands with its Description/Features
12.2.2.3. Financial Overview
12.2.2.4. Strategic Overview/Recent Developments
12.2.2.5. SWOT Analysis
12.2.3. Sartorius AG
12.2.3.1. Company Overview
12.2.3.2. Product Portfolio/Brands with its Description/Features
12.2.3.3. Financial Overview
12.2.3.4. Strategic Overview/Recent Developments
12.2.3.5. SWOT Analysis
12.2.4. Thermo Fisher Scientific Inc.
12.2.4.1. Company Overview
12.2.4.2. Product Portfolio/Brands with its Description/Features
12.2.4.3. Financial Overview
12.2.4.4. Strategic Overview/Recent Developments
12.2.4.5. SWOT Analysis
12.2.5. Merck KGaA
12.2.5.1. Company Overview
12.2.5.2. Product Portfolio/Brands with its Description/Features
12.2.5.3. Financial Overview
12.2.5.4. Strategic Overview/Recent Developments
12.2.5.5. SWOT Analysis
12.2.6. Charles River Laboratories
12.2.6.1. Company Overview
12.2.6.2. Product Portfolio/Brands with its Description/Features
12.2.6.3. Financial Overview
12.2.6.4. SWOT Analysis
12.2.7. Yokogawa Electric Corporation
12.2.7.1. Company Overview
12.2.7.2. Product Portfolio/Brands with its Description/Features
12.2.7.3. Financial Overview
12.2.7.4. SWOT Analysis
12.2.8. Carl Zeiss AG
12.2.8.1. Company Overview
12.2.8.2. Product Portfolio/Brands with its Description/Features
12.2.8.3. Financial Overview
12.2.8.4. Strategic Overview/Recent Developments
12.2.8.5. SWOT Analysis
List of Tables
Table 01: Global Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 02: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
Table 03: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
Table 04: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
Table 05: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
Table 06: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
Table 07: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
Table 08: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
Table 09: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
Table 10: Global Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Region, 2017-2031
Table 11: U.S. Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 12: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
Table 13: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
Table 14: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
Table 15: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
Table 16: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
Table 17: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
Table 18: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
Table 19: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
Table 20: Europe Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 21: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
Table 22: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
Table 23: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
Table 24: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
Table 25: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
Table 26: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
Table 27: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
Table 28: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
Table 29: Europe Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017-2031
Table 30: China Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 31: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
Table 32: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
Table 33: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
Table 34: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
Table 35: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
Table 36: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
Table 37: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
Table 38: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
Table 39: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by End-user, 2017-2031
Table 40: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017-2031
Table 41: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Oncology & Immune-oncology, 2017-2031
Table 42: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Cardiovascular & Metabolic Diseases, 2017-2031
Table 43: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Immunology, 2017-2031
Table 44: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Rare Diseases, 2017-2031
Table 45: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Neurological Diseases, 2017-2031
Table 46: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Others, 2017-2031
Table 47: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, by Workplace, 2017-2031
List of Figures
Figure 01: Growth in Adoption of CyTOF in National Clinical Trials
Figure 02: National Clinical Trials Citing CyTOF Technology, by Research Area, 2022
Figure 03: Number of Clinical Trials, by Platform, 2022
Figure 04: Global Image-based Cytometry in Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
Figure 05: Global Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
Figure 06: Global Image-based Cytometry in Cell Analysis Market (US$ Mn), by Biotechnology & Pharmaceutical Companies, 2017-2031
Figure 07: Global Image-based Cytometry in Cell Analysis Market (US$ Mn), by Academia, 2017-2031
Figure 08: Global Image-based Cytometry in Cell Analysis Market (US$ Mn), by Cosmetic Industry, 2017-2031
Figure 09: Global Image-based Cytometry in Cell Analysis Market (US$ Mn), by Contract Research Organizations, 2017-2031
Figure 10: Global Image-based Cytometry in Cell Analysis Market (US$ Mn), by Contract Development & Manufacturing Organizations, 2017-2031
Figure 11: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 12: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
Figure 13: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by Oncology & Immune-oncology, 2017-2031
Figure 14: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by Cardiovascular & Metabolic Diseases, 2017-2031
Figure 15: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by Immunology, 2017-2031
Figure 16: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by Rare Diseases, 2017-2031
Figure 17: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by Neurological Diseases, 2017-2031
Figure 18: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by Others, 2017-2031
Figure 19: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Analysis and Forecast, by Workplace, 2022 and 2031
Figure 20: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
Figure 21: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by Target Identification, 2017-2031
Figure 22: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by Hit Generation & Lead Identification, 2017-2031
Figure 23: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by Lead Optimization, 2017-2031
Figure 24: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by In Vitro Preclinical Studies, 2017-2031
Figure 25: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by In Vivo Preclinical Studies, 2017-2031
Figure 26: Global Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market (US$ Mn), by Clinical Studies, 2017-2031
Figure 27: Global Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Region, 2022 and 2031
Figure 28: Global Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Region, 2023-2031
Figure 29: U.S. Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
Figure 30: U.S. Image-based Cytometry in Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
Figure 31: U.S. Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
Figure 32: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 33: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
Figure 34: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
Figure 35: U.S. Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
Figure 36: Europe Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
Figure 37: Europe Image-based Cytometry in Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
Figure 38: Europe Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
Figure 39: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 40: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
Figure 41: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
Figure 42: Europe Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
Figure 43: Europe Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
Figure 44: Europe Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
Figure 45: China Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
Figure 46: China Image-based Cytometry in Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
Figure 47: China Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
Figure 48: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 49: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
Figure 50: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
Figure 51: China Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
Figure 52: Rest of the World Image-based Cytometry in Cell Analysis Market Value (US$ Mn) Forecast, 2017-2031
Figure 53: Rest of the World Image-based Cytometry in Cell Analysis Market Value Share Analysis, by End-user, 2022 and 2031
Figure 54: Rest of the World Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by End-user, 2023-2031
Figure 55: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Therapeutic Area, 2022 and 2031
Figure 56: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Therapeutic Area, 2023-2031
Figure 57: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Value Share Analysis, by Workplace, 2022 and 2031
Figure 58: Rest of the World Biotechnology & Pharmaceutical Companies Image-based Cytometry in Cell Analysis Market Attractiveness Analysis, by Workplace, 2023-2031
Figure 59: Global Image-based Cytometry in Cell Analysis Market Share Analysis, by Company, 2022
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Image Based Cytometry in Cell Analysis Market
*86 figures and 60 tables includes